Related Experiment Video
Updated: Feb 26, 2026
Analysis of the Lipid Composition of Mycobacteria by Thin Layer Chromatography
Published on: April 16, 2021
Effect of phenolic glycolipids from Mycobacterium kansasii on proinflammatory cytokine release. A structure-activity
Hassan R H Elsaidi1, Todd L Lowary1
1Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton , AB , Canada T6G 2G2 .
Abstract:
The cell wall of pathogenic mycobacteria is abundant with virulence factors, among which phenolic glycolipids (PGLs) are prominent examples. Mycobacterium kansasii, an important opportunistic pathogen, produces seven PGLs and their effect on the release of important proinflammatory cytokines that mediate disease progression has not been investigated. We previously showed that proinflammatory cytokines are modulated by PGLs from M. tuberculosis, M. leprae and M. bovis. In this paper we describe the synthesis of a series of 17 analogs of M. kansasii PGLs containing a truncated aglycone. Subsequently, the effect of these compounds on the release of proinflammatory cytokines (TNF-α, IL-6, IL-1β, MCP-1) and nitric oxide (NO) was evaluated. These compounds exerted an immunoinhibitory effect on the release of the tested cytokines. The concentration-dependent inhibitory profile of the tested molecules was also found to be dependent on the methylation pattern of the molecule and was mediated via toll-like receptor (TLR)-2. This study led to the discovery of a glycolipid (18) that shows promising potent anti-inflammatory properties making it a potential candidate for further optimization of its anti-inflammatory profile.
Insights
Researchers synthesized phenolic glycolipid analogs from Mycobacterium kansasii and found they inhibit proinflammatory cytokines via toll-like receptor 2, discovering a potent anti-inflammatory glycolipid candidate.
Area of Science:
- Immunology
- Microbiology
- Medicinal Chemistry
Background:
- Pathogenic mycobacteria cell walls contain virulence factors, including phenolic glycolipids (PGLs).
- Mycobacterium kansasii produces seven PGLs, but their impact on proinflammatory cytokine release is unknown.
- Previous research indicated PGLs from other mycobacteria modulate cytokine release.
Purpose of the Study:
- To synthesize and evaluate analogs of Mycobacterium kansasii PGLs.
- To investigate the effect of these analogs on the release of proinflammatory cytokines (TNF-α, IL-6, IL-1β, MCP-1) and nitric oxide (NO).
- To identify potential anti-inflammatory compounds derived from M. kansasii PGLs.
Main Methods:
- Synthesis of 17 analogs of M. kansasii PGLs with truncated aglycones.
- Evaluation of the immunoinhibitory effect of synthesized compounds on cytokine and nitric oxide release.
- Analysis of the concentration-dependent inhibitory profile, methylation pattern influence, and toll-like receptor (TLR)-2 mediation.
Main Results:
- The synthesized analogs demonstrated an immunoinhibitory effect on the release of tested cytokines.
- The inhibitory effect was concentration-dependent and influenced by the methylation pattern of the molecules.
- The mechanism of inhibition involved toll-like receptor (TLR)-2.
- A specific glycolipid (compound 18) was identified with potent anti-inflammatory properties.
Conclusions:
- Synthesized M. kansasii PGL analogs possess immunoinhibitory properties.
- The anti-inflammatory activity is mediated via TLR-2 and influenced by molecular structure.
- Compound 18 represents a promising candidate for developing novel anti-inflammatory therapeutics.
